Supplementary data: Personalized drug screening and risk assessment in patient-derived gastroenteropancreatic neuroendocrine neoplasms

Citation: Auernhammer, Christoph J and Wang, Katharina and Maccio, Umberto and Knösel, Thomas and Hungbauer, Maximilian P and Schilbach, Katharina and Maurer, Julian and Peischer, Lea and Reul, Astrid and Kuzmenko, Elena and Luca, Edlira and Hamati, Julia and Vetter, Diana and Oberholzer, Jose and Fritsch, Ralph and Pacak, Karel and Grossman, Ashley B and Beuschlein, Felix and Reincke, Martin and Hantel, Constanze and Zitzmann, Kathrin and Nölting, Svenja: Supplementary data: Personalized drug screening and risk assessment in patient-derived gastroenteropancreatic neuroendocrine neoplasms. 30. December 2025. Open Data LMU. 10.5282/ubm/data.747

Abstract

This dataset contains supplementary material to the associated article “Personalized Drug Screening and Risk Assessment in Patient-Derived Gastroenteropancreatic Neuroendocrine Neoplasms”. The article was published in the Journal of Clinical Endocrinology and Metabolism. Data to: Christoph J Auernhammer, Katharina Wang, Umberto Maccio, Thomas Knösel, Maximilian P Hungbauer, Katharina Schilbach, Julian Maurer, Lea Peischer, Astrid Reul, Elena Kuzmenko, Edlira Luca, Julia Hamati, Diana Vetter, Jose Oberholzer, Ralph Fritsch, Karel Pacak, Ashley B Grossman, Felix Beuschlein, Martin Reincke, Constanze Hantel, Kathrin Zitzmann, Svenja Nölting, Personalized drug screening and risk assessment in patient-derived gastroenteropancreatic neuroendocrine neoplasms, The Journal of Clinical Endocrinology & Metabolism, 2026; https://doi.org/10.1210/clinem/dgaf705

Uncontrolled Keywords

neuroendocrine tumor, primary culture, precision medicine, personalized drug testing

• Item Type: Data
• Contact Person: Wang, Katharina
• E-Mail of Contact: K.Wang at med.uni-muenchen.de
• Subjects: Medicine
• Dewey Decimal Classification: 600 Technology, Medicine > 610 Medical sciences and medicine